Interferon-γ With Donor Leukocyte Infusion

A Phase 2 Trial of Interferon-γ (IFN-γ) in Combination With Donor Leukocyte Infusion (DLI) to Treat Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

What's the purpose of the trial?

This phase 2 study aims to confirm the efficacy seen in the prior phase 1 trial, and further contribute to this effort through the collection of leukemia cells pre- and post- in vivo IFN-γ therapy. As in the previously conducted phase 1 trial, this trial will test whether leukemia blasts were responsive to IFN-γ in vitro and in vivo, with single-cell RNA sequencing (scRNAseq) conducted to understand the transcriptomic changes induced by IFN-γ in leukemia cell subsets, including those with stem cell characteristics.
Trial status

Accepting patients

Phase
Phase 2
Enrollment
45
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Donor Lymphocyte Infusion (DLI) is an infusion of lymphocytes (usually T cells) that come from a donor.
  • IFN-γ (interferon gamma-1b) injection is a manufactured version of a protein made by white blood cells called interferon that may help the body fight infections.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Interferon-γ + Donor Leukocyte Infusion

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.